HK1080408B - Use of brimonidine in the treatment of dementia and parkinsons disease - Google Patents

Use of brimonidine in the treatment of dementia and parkinsons disease Download PDF

Info

Publication number
HK1080408B
HK1080408B HK06100172.4A HK06100172A HK1080408B HK 1080408 B HK1080408 B HK 1080408B HK 06100172 A HK06100172 A HK 06100172A HK 1080408 B HK1080408 B HK 1080408B
Authority
HK
Hong Kong
Prior art keywords
alpha
brimonidine
neurons
apoptosis
disease
Prior art date
Application number
HK06100172.4A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1080408A1 (en
Inventor
William G. Tatton
Larry A. Wheeler
Daniel W. Gil
John E. Donello
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of HK1080408A1 publication Critical patent/HK1080408A1/en
Publication of HK1080408B publication Critical patent/HK1080408B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
HK06100172.4A 2002-10-08 2003-10-07 Use of brimonidine in the treatment of dementia and parkinsons disease HK1080408B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41703102P 2002-10-08 2002-10-08
US417031P 2002-10-08
PCT/US2003/031842 WO2004032934A1 (en) 2002-10-08 2003-10-07 Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons

Publications (2)

Publication Number Publication Date
HK1080408A1 HK1080408A1 (en) 2006-04-28
HK1080408B true HK1080408B (en) 2008-08-08

Family

ID=32093952

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100172.4A HK1080408B (en) 2002-10-08 2003-10-07 Use of brimonidine in the treatment of dementia and parkinsons disease

Country Status (20)

Country Link
US (1) US20040116436A1 (cg-RX-API-DMAC10.html)
EP (1) EP1549314B1 (cg-RX-API-DMAC10.html)
JP (1) JP2006504741A (cg-RX-API-DMAC10.html)
KR (1) KR20050056235A (cg-RX-API-DMAC10.html)
CN (1) CN100370988C (cg-RX-API-DMAC10.html)
AT (1) ATE380551T1 (cg-RX-API-DMAC10.html)
AU (2) AU2003279874A1 (cg-RX-API-DMAC10.html)
BR (1) BR0314541A (cg-RX-API-DMAC10.html)
CA (1) CA2501348A1 (cg-RX-API-DMAC10.html)
DE (1) DE60318081T2 (cg-RX-API-DMAC10.html)
ES (1) ES2297233T3 (cg-RX-API-DMAC10.html)
HK (1) HK1080408B (cg-RX-API-DMAC10.html)
IL (1) IL167848A (cg-RX-API-DMAC10.html)
MX (1) MXPA05003665A (cg-RX-API-DMAC10.html)
NO (1) NO20051664L (cg-RX-API-DMAC10.html)
NZ (1) NZ539329A (cg-RX-API-DMAC10.html)
PL (1) PL376347A1 (cg-RX-API-DMAC10.html)
RU (1) RU2332218C2 (cg-RX-API-DMAC10.html)
WO (1) WO2004032934A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200502745B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
DE102009043750A1 (de) * 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
US10022341B2 (en) * 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота
JP2019526055A (ja) * 2016-08-01 2019-09-12 コグノプティックス， インコーポレイテッド 眼組織におけるタウタンパク質を検出するためのシステムおよび方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
EP1365811A2 (en) * 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components

Also Published As

Publication number Publication date
RU2005114505A (ru) 2005-10-27
IL167848A (en) 2010-11-30
ATE380551T1 (de) 2007-12-15
NZ539329A (en) 2007-11-30
EP1549314B1 (en) 2007-12-12
CN100370988C (zh) 2008-02-27
ZA200502745B (en) 2006-07-26
WO2004032934A1 (en) 2004-04-22
ES2297233T3 (es) 2008-05-01
PL376347A1 (en) 2005-12-27
CN1703222A (zh) 2005-11-30
US20040116436A1 (en) 2004-06-17
AU2003279874A1 (en) 2004-05-04
MXPA05003665A (es) 2005-06-08
DE60318081D1 (de) 2008-01-24
AU2010200730A1 (en) 2010-03-18
NO20051664L (no) 2005-05-31
HK1080408A1 (en) 2006-04-28
EP1549314A1 (en) 2005-07-06
KR20050056235A (ko) 2005-06-14
BR0314541A (pt) 2005-07-26
RU2332218C2 (ru) 2008-08-27
DE60318081T2 (de) 2008-11-06
JP2006504741A (ja) 2006-02-09
CA2501348A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2009238370B2 (en) Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration
AU2010200730A1 (en) Method of using (2-imidazolin-2-ylamino) quinoxalines in the treatment of dementia and parkinsons
EP1345608B1 (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
CA3088178A1 (en) Treatment of liver diseases
KR20230050363A (ko) 질환의 치료에 있어서 btk 저해제의 용도
US10537567B2 (en) Kinase inhibitors for treatment of disease
CA2568213C (en) Composition and method for the treatment of tauopathies
AU2011239265A1 (en) Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration
HK1081880B (en) Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121007